BNET Industries

Orexigen Therapeutics Inc.

(OREX) is in the Pharma Industry

Market Cap:$319.4M
Last Fiscal Year Sales:$88.0K
  • Public
  • US
Dow Jones Description

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.

founding CEO
Eckard Weber
Number of Employees 25
Contact Information

12481 High Bluff Drive

Suite 160

San Diego, California 92130

www.orexigen.co...

(858) 436-8600

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

Recent Events

  • Orexigen Therapeutics Appoints Dawn Viveash As Head Of Global Regulatory Affairs - Quick Facts

    11/23/09 - Mgmt. Change Entering - Legal - View Story

  • OrexigenR Therapeutics Announces Third Quarter 2009 Financial Results - Management to host call and webcast...

    11/05/09 - Financial Announcement - View Story

  • OrexigenR Therapeutics Announces Second Quarter 2009 Financial Results

    8/09/09 - Financial Announcement - View Story

  • Orexigen slims patients with addiction-drug combo

    7/20/09 - Mgmt. Change Leaving - Other - View Story

News & Analysis

orexigen therapeutics inc. - All News and Analysis

Decision Makers

Name (plus bio) Position
Eckard Weber founding CEO
Gary D. Tollefson Chief Executive Officer
Brian H. Dovey Director
Louis C. Bock member

Dr. Weber is a partner at Domain Associates where he creates companies around promising new pharmaceutical products. He has been founding CEO of multiple biopharmaceutical companies in the Domain portfolio including Cytovia, Acea, Novacea, NovaCardia, Novalar, Orexigen, Domain Antibacterial Acquisition Corporation, Ascenta, Ocera, Syndax, Tragara, Tobira, Sonexa and Calixa. He currently serves as interim CEO of Sonexa and Calixa, two seed-stage biopharmaceutical companies. He is Chairman of the Board at NovaCardia, Orexigen, Ocera, Ascenta, Tobira and Syndax. He was Chairman of Peninsula until it’s sale to Johnson & Johnson in 2005, Chairman of Cerexa until it’s sale to Forest Laboratories in January 2007, and a Board member of Conforma and Cabrellis until their sales to Biogen-IDEC and Pharmion, respectively. In addition, he is a board member of DiObex and BioVascular, Inc. Until 1995, Mr. Weber was a tenured Professor of Pharmacology at the University of California at Irvine. He has over 20 years of drug discovery and development experience and has been a consultant to biotechnology and pharmaceutical companies. He is the inventor or co-inventor of over 40 patents and patent applications, and he has published over 130 papers in scientific periodicals.

Organization Position Status
Orexigen Therapeutics, Inc. founding CEO Current
Novac founding CEO Current
Syndax Pharmaceuticals, Inc. Interim CEO Current
Tragara Pharmaceuticals, Inc. Interim CEO Current
Orexigen Co Interim President and Chief Executive Officer Current
Orexigen Co Chairman, Domain Associates, Partner Former
Domain Associates LLC Partner Current
Sequel Pharmaceuticals, Inc. Chairman of The Board Current
Syndax Pharmaceuticals, Inc. Chairman of the Board Current
Cerexa, Inc. Chairman Former
Ocera Chairman of the Board Current
Ascenta Therapeutics, Inc. Chairman of the Board Current
Novacardia, Inc Chairman of the Board of Directors Current
Novacea, Inc. Chairman Current
NovaCardia, Inc. Chairman Current
Therapeutics Incorporated Board Member Current
Biovascular Inc Board Member Current
Diobex, Inc Board Member Current
Tragara Pharmaceuticals, Inc. Board of Directors Current
Cabrellis Pharmaceuticals Corporation Board of Directors Current
Novacea, Inc. founding CEO Former
NovaCardia, Inc. founding CEO Former
Novalar Pharmaceuticals, Inc. founding CEO Former
Ascenta Therapeutics, Inc. founding CEO Former
University of California Professor Former
University of California, Irvine Professor of Pharmacology Former
Peninsula Pharmaceuticals, Inc. Chairman Former
Tobira Therapeutics Chairman of the Board Former
Ocera Therapeutics, Inc. Chairman of the Board Former
The Peninsula Chairman Former
Conforma Therapeutics Corporation Board Member Former
Stanford University School of Medicine Postdoctoral Training Former

Organization Position Status
Orexigen Therapeutics, Inc. Chief Executive Officer Current
Orexigen Co President, Chief Executive Officer and Director Current
Cortex Pharmaceuticals, Inc. Director and Consultant Current
Westbury Partners Director Current
Cortex Pharmaceuticals, Inc. Director Current
Insys Therapeutics, Inc Member of the Board of Directors Current
Avera Pharmaceuticals, Inc. Board of Directors Current
XenoPort Inc. Director Current
Cypress Bioscience, Inc. Member Current
XenoPort Inc. Member Current
Lilly Research Laboratories Vice President Former
Eli Lilly and Company Former
Department of Psychiatry Chairperson Former
Orexigen Co Board of Directors Former
University of Minnesota PH.D. In Psychiatry Former
University of Minnesota B.A. Former
Cortex Pharmaceuticals, Inc. Member Former
Orexigen Co Member Former

Organization Position Status
Domain Associates LLC Partner Current
Valley Forge Pharmaceuticals, Inc. Current
The Wistar Institute Chair Current
Univax Biologics Chairman Current
Creative BioMolecules, Inc. Chairman Current
Skinmedica Acne System Board of Directors Current
Germantown Academy Board of Directors Current
Biovascular Inc Board of Directors Current
Ocera Therapeutics, Inc. Board of Directors Current
Orqis Medical Corporation Board of Directors Current
Orexigen Co Board of Directors Current
Align Technology, Inc. Director Current
Vivus, Inc. Board Member Current
ISTA Pharmaceuticals, Inc. Board Member Current
SkinMedica, Inc. Director Current
Connetics Corporation Board Member Current
Orexigen Therapeutics, Inc. Director Current
US Bioscience Board Member Current
BAS Medical Director Current
Geron Corporation Board Member Current
Cardiac Science Corporation Board Member Current
Trimeris, Inc. Board Member Current
Resound Corp Board Member Current
Symphony Medical, Inc. Director Current
Kauffman Fellows Program at the Center for Venture Education Director Current
Germantown Academy Trustee Emeritus Current
Howmedica, Inc. President Former
Howmet Corporation President Former
Howmedica, Inc. management positions Former
Howmet Corporation management positions Former
Neose Technologies, Inc. Board of Directors Current
Sanofi-Aventis Former
Burnham Institute for Medical Research Board of Directors Former
The Burnham Institute Board Member Former
Harvard Business School M.B.A Former
Harvard Business School M.B.A. degree Former
Colgate University B.A. Former
Burnham Institute for Medical Research Trustee Former
Domain Associates LLC member Former

Organization Position Status
Atlantic Corporation Managing Director Current
Dynavax Technologies Corp. Board of Directors Current
Somaxon Pharmaceuticals, Inc. Board of Directors Current
Technology Vision Group LLC Board of Directors Current
diaDexus, Inc. Director Current
Ascenta Therapeutics, Inc. Director Current
Zogenix, Inc. Board of Directors Current
SGX Pharmaceuticals, Inc. Director Current
Horizon Therapeutics, Inc. Director Current
Orexigen Co Board of Directors Current
Dynavax Technologies Corp. Investor Current
Orexigen Therapeutics, Inc. member Current
Somaxon Pharmaceuticals, Inc. member Current
diaDexus, Inc. member Current
Ascenta Therapeutics, Inc. member Current
Ba Venture Partners Managing Director Former
Genentech, Inc. research associate Former
California State University M.B.A. Former
California State University B.S. In Biology Former
Seattle Genetics, Inc. member Former
advertisement
     OREX $6.79 0.00 (0.00% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 891,069
Shares Outstanding 47.04M
Market Cap 319.4M
Year High 10.83
Year Low 1.55
Earnings Per Share -2.04
P/E Ratio -3.33
Dividend N/A
Yield N/A
IndustryTop Rated
advertisement
Click Here